Indication
Prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant

Medicine details

Medicine name:
letermovir (Prevymis)
SMC ID:
1338/18
Pharmaceutical company
MSD
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Advice due date:
11 March 2019
SMC meeting date:
05 June 2018
Patient group submission deadline:
02 April 2018